Clinical trial
Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
NCT00425204 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00425204 |
|---|---|
| Title | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment |
| Official title | A Multi-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Solid Tumors, Advanced Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Panitumumab (ABX-EGF) |
| Enrollment | 31 |
| Start date | Mar 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jan 22, 2007 |
| Last update posted | Sep 15, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: